In situ vaccination with a tlr9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma

Cancer Discovery

Volumn 8, Issue 10, 2018, Pages 1258-1269

  Frank, Matthew J ^a   Reagan, Patrick M ^b   Bartlett, Nancy L ^c   Gordon, Leo I ^d   Friedberg, Jonathan W ^b   Czerwinski, Debra K ^a   Long, Steven R ^a   Hoppe, Richard T ^a   Janssen, Robert ^e   Candia, Albert F ^e   Coffman, Robert L ^e   Levy, Ronald ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Washington University in St Louis School of Medicine   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Dynavax Technologies Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GRANZYME B; SD 101; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EFFECTOR CELL; FATIGUE; FEMALE; FEVER; FINE NEEDLE ASPIRATION BIOPSY; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION; HEADACHE; HISTOLOGY; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LOW ENERGY RADIATION; LYMPHOMA; MALAISE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NIGHT SWEAT; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMACYTOID DENDRITIC CELL; RADIATION DOSE; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SORE THROAT; TFH CELL; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UPREGULATION; VACCINATION; CLINICAL TRIAL; IMMUNOTHERAPY; METABOLISM; MIDDLE AGED; NONHODGKIN LYMPHOMA; PROCEDURES; YOUNG ADULT;

ADULT; AGED; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; TOLL-LIKE RECEPTOR 9; VACCINATION; YOUNG ADULT;

EID: 85054354559     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-18-0743     Document Type: Article

References (36)

1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531–44.
2. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411–22.
3. Wolchok JD, Rollin L, Larkin J. Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017;377:2503–4.
4. Hammerich L, Binder A, Brody JD. In situ vaccination: cancer immunotherapy both personalized and off-the-shelf. Mol Oncol 2015;9: 1966–81.
5. Hammerich L, Bhardwaj N, Kohrt HE, Brody JD. In situ vaccination for the treatment of cancer. Immunotherapy 2016;8:315–30.
6. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdörfer B, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002;169:3892–9.
7. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 2007;179: 2493–500.
8. Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2009;113:3546–52.
9. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013;123:2447–63.
10. Sagiv-Barfi I, Kohrt HE, Burckhardt L, Czerwinski DK, Levy R. Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. Blood 2015;125:2079–86.
11. Sagiv-Barfi I, Czerwinski DK, Levy S, Alam IS, Mayer AT, Gambhir SS, et al. Eradication of spontaneous malignancy by local immunotherapy. Sci Transl Med 2018;10:pii:eaan4488.
12. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010;28: 4324–32.
13. Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J Immunother. 2009;32:622–31.
14. Zent CS, Smith BJ, Ballas ZK, Wooldridge JE, Link BK, Call TG, et al. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:211–7.
15. Hirsh V, Paz-Ares L, Boyer M, Rosell R, Middleton G, Eberhardt WE, et al. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:2667–74.
16. Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JS, BlasinskaMorawiec M, et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2012;23:72–7.
17. Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature 2017;543:723–7.
18. Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 2015;41:503–10.
19. Rees GJ. Abscopal regression in lymphoma: a mechanism in common with total body irradiation? Clin Radiol 1981;32:475–80.
20. Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 2014;15:424–35.
21. Wang S, Campos J, Gallotta M, Gong M, Crain C, Naik E, et al. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci U S A 2016;113:E7240–E9.
22. Leung ACF, Kummar S, Agarwala SS, Nemunaitis JJ, Gonzalez R, Drabick JJ. Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naïve & experienced metastatic melanoma patients. J Clin Oncol 2017;35:9550.
23. Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. Cancer Immunol Res 2014;2:720–4.
24. Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, et al. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Ann Oncol 2018;29:1312–9.
25. Flowers C, Panizo C, Isufi I, Herrera AF, Okada C, Cull EH, et al. Intratumoral G100 induces systemic immunity and abscopal tumor regression in patients with follicular lymphoma: results of a Phase 1/2 study examining G100 alone and in combination with pembrolizumab. Blood 2017;130:2771.
26. Smyth EC, Flavin M, Pulitzer MP, Gardner GJ, Costantino PD, Chi DS, et al. Treatment of locally recurrent mucosal melanoma with topical imiquimod. J Clin Oncol 2011;29:e809–11.
27. Broomfield SA, van der Most RG, Prosser AC, Mahendran S, Tovey MG, Smyth MJ, et al. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol 2009;182:5217–24.
28. Singh M, Khong H, Dai Z, Huang XF, Wargo JA, Cooper ZA, et al. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol 2014;193:4722–31.
29. Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 2015;11:1018–30.
30. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, et al. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol 2013;190:6681–93.
31. Whiteside TL. The role of regulatory T cells in cancer immunology. Immunotargets Ther 2015;4:159–71.
32. + T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003;94:1003–9.
33. McCoy MJ, Nowak AK, van der Most RG, Dick IM, Lake RA. Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer Immunol Immunother 2013;62:529–39.
34. Green MR, Kihira S, Liu CL, Nair RV, Salari R, Gentles AJ, et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A 2015;112: E1116–25.
35. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189–95.
36. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–86.